Ligand Pharmaceuticals Inc
LGND190.440USD
-1.250-0.65%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
3.74BMarket Cap
79.51P/E TTM
More Details of Ligand Pharmaceuticals Inc Company
Ligand Pharmaceuticals Incorporated is a biopharmaceutical company enabling scientific advancement through supporting the clinical development of medicines. It does this by financing, licensing its technologies or both. It operates two infrastructure-light royalty-generating IP platform technologies. Its Captisol platform technology is a chemically modified cyclodextrin with a structure designed to optimize the solubility and stability of drugs. This technology has enabled FDA-approved products, including Gilead’s Veklury, Amgen’s Kyprolis, Baxter’s Nexterone, and Acrotech Biopharma’s Evomela. Its NITRICIL platform technology facilitates tunable dosing, permitting an adjustable drug release profile to allow proprietary formulations that target a range of indications. Its technologies also include HepDirect, LTP and BEPro Technology Platform, and Pelican Expression Technology. It has multiple alliances, licenses and other business relationships with various pharmaceutical companies.
Ligand Pharmaceuticals Inc Info
Ticker SymbolLGND
Company nameLigand Pharmaceuticals Inc
IPO dateNov 18, 1992
CEODavis (Todd C)
Number of employees68
Security typeOrdinary Share
Fiscal year-endNov 18
Address555 Heritage Drive, Suite 200
CityJUPITER
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code33458
Phone18585507500
Websitehttps://www.ligand.com/
Ticker SymbolLGND
IPO dateNov 18, 1992
CEODavis (Todd C)
Company Executives of Ligand Pharmaceuticals Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
129.19K
+2034.00%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+1209.00%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-1325.00%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
8.84K
-1277.00%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+1209.00%
Dr. Martine Zimmermann, Pharm.D.
Dr. Martine Zimmermann, Pharm.D.
Independent Director
Independent Director
4.17K
-115.00%
Mr. Todd C. Davis
Mr. Todd C. Davis
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. John L. Lamattina, Ph.D.
Dr. John L. Lamattina, Ph.D.
Independent Director
Independent Director
--
--
Ms. Melanie J. Herman
Ms. Melanie J. Herman
Investor Relations
Investor Relations
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Jason M. Aryeh
Mr. Jason M. Aryeh
Independent Director
Independent Director
129.19K
+2034.00%
Dr. Stephen L. Sabba, M.D.
Dr. Stephen L. Sabba, M.D.
Independent Director
Independent Director
35.05K
+1209.00%
Mr. Andrew Reardon
Mr. Andrew Reardon
Chief Legal Officer
Chief Legal Officer
15.72K
-1325.00%
Dr. Nancy Ryan Gray, Ph.D.
Dr. Nancy Ryan Gray, Ph.D.
Independent Director
Independent Director
9.35K
--
Mr. Octavio (Tavo) Espinoza
Mr. Octavio (Tavo) Espinoza
Chief Financial Officer
Chief Financial Officer
8.84K
-1277.00%
Mr. Jason Haas
Mr. Jason Haas
Independent Director
Independent Director
6.86K
+1209.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Contract Revenue- Other
58.20M
50.41%
Kyprolis
11.62M
10.06%
Captisol
10.67M
9.24%
Filspari
9.08M
7.86%
Qarziba
5.98M
5.18%
Other
19.91M
17.25%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Contract Revenue- Other
58.20M
50.41%
Kyprolis
11.62M
10.06%
Captisol
10.67M
9.24%
Filspari
9.08M
7.86%
Qarziba
5.98M
5.18%
Other
19.91M
17.25%
Shareholding Stats
Updated: Fri, Jan 30
Updated: Fri, Jan 30
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.51%
Janus Henderson Investors
5.30%
Nomura Investment Management Business Trust
3.82%
State Street Investment Management (US)
3.81%
Other
63.22%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
13.35%
The Vanguard Group, Inc.
10.51%
Janus Henderson Investors
5.30%
Nomura Investment Management Business Trust
3.82%
State Street Investment Management (US)
3.81%
Other
63.22%
Shareholder Types
Shareholders
Proportion
Investment Advisor
57.90%
Investment Advisor/Hedge Fund
38.29%
Research Firm
3.68%
Individual Investor
2.27%
Bank and Trust
1.68%
Pension Fund
1.63%
Hedge Fund
0.72%
Family Office
0.16%
Sovereign Wealth Fund
0.10%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
591
20.54M
104.36%
-316.11K
2025Q3
541
20.07M
102.40%
-232.93K
2025Q2
535
19.71M
102.13%
-738.05K
2025Q1
554
19.82M
102.82%
-711.89K
2024Q4
546
19.28M
100.16%
-1.51M
2024Q3
543
19.17M
104.83%
-583.22K
2024Q2
527
18.31M
101.74%
-865.78K
2024Q1
520
17.60M
99.35%
-393.03K
2023Q4
527
16.97M
97.29%
-861.76K
2023Q3
515
17.24M
99.38%
-910.17K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
2.63M
13.35%
-27.96K
-1.05%
Sep 30, 2025
The Vanguard Group, Inc.
2.07M
10.53%
-13.09K
-0.63%
Sep 30, 2025
Janus Henderson Investors
1.04M
5.3%
-18.36K
-1.73%
Sep 30, 2025
Nomura Investment Management Business Trust
751.79K
3.82%
-174.77K
-18.86%
Sep 30, 2025
State Street Investment Management (US)
749.36K
3.81%
-394.00
-0.05%
Sep 30, 2025
Chicago Capital, LLC
568.61K
2.89%
-3.21K
-0.56%
Sep 30, 2025
Dimensional Fund Advisors, L.P.
523.91K
2.66%
-180.61K
-25.64%
Sep 30, 2025
MFS Investment Management
541.85K
2.75%
+202.10K
+59.49%
Sep 30, 2025
Stephens Investment Management Group, LLC
554.54K
2.82%
-50.27K
-8.31%
Sep 30, 2025
Congress Asset Management Company, LLP
667.31K
3.39%
+19.37K
+2.99%
Sep 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Franklin Genomic Advancements ETF
4.21%
Invesco Pharmaceuticals ETF
3.2%
State Street SPDR S&P Pharmaceuticals ETF
3.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2.74%
Virtus LifeSci Biotech Products ETF
2.67%
Invesco S&P SmallCap Health Care ETF
2.3%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
1.64%
iShares U.S. Pharmaceuticals ETF
1.38%
First Trust Multi-Manager Small Cap Opportunities ETF
1.09%
View more
Franklin Genomic Advancements ETF
Proportion4.21%
Invesco Pharmaceuticals ETF
Proportion3.2%
State Street SPDR S&P Pharmaceuticals ETF
Proportion3.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion2.74%
Virtus LifeSci Biotech Products ETF
Proportion2.67%
Invesco S&P SmallCap Health Care ETF
Proportion2.3%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.73%
Invesco Dorsey Wright Healthcare Momentum ETF
Proportion1.64%
iShares U.S. Pharmaceuticals ETF
Proportion1.38%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion1.09%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
